Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

SHR-1653 as a novel highly potent and selective OTR antagonist

Aug. 14, 2019

Eloxx Pharmaceuticals initiates phase II study for ELX-02 in cystinosis

Aug. 6, 2019

Aronora opens phase II study of AB-002 in end-stage renal disease patients on chronic hemodialysis

Aug. 1, 2019

Roystonea regia lipid extract reduces lower urinary tract symptoms in men with BPH

July 26, 2019

Regulus outlines FDA requirements to reinitiate MAD studies with RGLS-4326

July 24, 2019

BioMarin Pharmaceutical identifies hydroxyacid oxidase 1 inhibitors

July 24, 2019

DiaMedica reports phase Ib interim data on DM-199 in chronic kidney disease

June 20, 2019

Arch Biopartners initiates phase I study of Metablok

June 20, 2019

Corvidia opens phase II study of ziltivekimab to reduce inflammation in chronic renal disease

June 14, 2019

RNA triad prevents dialysis-induced fibrosis

June 14, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...